Year: 2023

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics...

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of MedicineNEW YORK and...

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates...

TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™...

Imprivata Launches First Digital Identity Maturity Model and Assessment Developed for Healthcare IT, Security, and Clinical Leadership

Free, one-of-a-kind resources deliver actionable guidance to build a comprehensive digital identity strategy that improves care quality, reduces cyber risks,...

Michael Blackton Appointed as Senior Vice President of Elektrofi’s Technical Operations as Elektrofi Continues to Bolster Leadership Bench with Industry Veterans

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Today Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, welcomed...

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

error: Content is protected !!